Pure CBD is not internationally controlled
The INCB’s 2026 notice states that pure CBD is not controlled under the international drug control conventions.
Patients. Evidence. Rights.
CBD is a Human Right.
European governments are being urged to restrict CBD as a “drug precursor” — a claim not supported by the currently available evidence, advanced without public debate. We are an open coalition of patient organisations. We ask for transparent, evidence-based decisions and proportionate regulation — not covert prohibition.
[live number] verified signatures 5 founding patient organisations
- Open patient coalition
- Evidence-based
- Pan-European
to be supplied (consent-verified)
-
Verified signatures
Signatures are verified by independent moderators.
-
Founding patient organisations
Led by patient groups across Europe.
-
Transparent campaign governance
Decisions, funding and processes are publicly disclosed.
The current threat
A precursor claim the evidence does not carry.
Following an internal INCB notification (PP Notice No. 1/2026) and China’s 2024 designation of CBD as a drug precursor, the Czech government has moved a proposal to restrict CBD on “precursor” grounds into its inter-ministerial comment procedure — an administrative path, without open public debate. If one member state converts this framing into law, others primed by the same notice may follow.
The INCB’s own notice concedes the precursor evidence is “limited” — and notes that pure CBD is not controlled under the international drug control conventions.
INCB · PP Notice No. 1/2026, 24 Feb 2026
The record
What the evidence says
The INCB notice says the evidence is “limited”
The same notice concedes the evidence for CBD’s use as a starting material is “limited”.
The documented HHC case used industrial hemp
The single documented criminal case — an HHC network in Romania (2022–2023) — used industrial hemp, not CBD.
What we ask
Five demands. None of them radical.
The coalition does not argue that CBD should be unregulated. We argue that restrictions must not be introduced covertly, administratively, or on evidence that does not withstand scrutiny.
Publish the evidence.
A full, transparent assessment of the scientific record before any restriction is proposed or adopted.
No covert restrictions.
No administrative measures without open public debate, a proportionality test, and a patient-impact assessment.
Regulate, don’t prohibit.
Proportionate rules: quality standards, contaminant testing, clear labelling, age restrictions where relevant.
Act on the real threat.
Enforcement against synthetic cannabinoids sold as “collector’s items” — not against tested products patients rely on.
A seat at the table.
Patient organisations formally consulted in every decision that affects access to treatment.
Patient voices
The people a restriction would actually reach
Testimonials are published only after written consent under the coalition protocol. Until then, these are the stories we are gathering — never invented quotes.
Slot 1 · Czech Republic
Senior patient, chronic pain
Awaiting consented testimonial
Slot 2 · Spain
Parent of a child with treatment-resistant epilepsy
Awaiting consented testimonial
Slot 3 · France
Veteran living with PTSD, prescribed medical cannabis containing CBD
Awaiting consented testimonial
Your story can change this debate
If CBD is part of how you manage your health, and you are willing to tell that story — named or anonymised — write to coalition@cbdhumanright.org. We will explain the consent process before anything is recorded.
Why transparency matters
We hold ourselves to the standard we demand.
This campaign asks governments to decide transparently. The same rules apply to us: we publish our funding and independence policy, name our coalition members, and process patient data only with explicit consent and only for this appeal.
Add your name to the appeal
An open call from an international coalition of patient organisations. Sign as a citizen, patient, carer, or healthcare professional — or ask your organisation to join.
Sign the appeal- KOPAC (Czech Republic)
- Dosemociones (Spain)
- Aube (Canada/France)
- Verein Medcan (Switzerland)
- PatientsCann (United Kingdom)
Further patient organisations and individuals may join at any time — the appeal is an open call.